Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials

References

• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41M:3–14.
   Google Scholar
• Cancerresearchuk.org. Ovarian cancer statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed 66, 2018.
   Google Scholar
• Seer.cancer.gov. Ovarian cancer-cancer stat facts. Available from: https://seer.cancer.gov/statfacts/html/ovary.html. Accessed 65, 2018.
   Google Scholar
• Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(2):115–132.26808342
   PubMed Web of Science ®Google Scholar
• Fan GY, Wang Y. Clinical analysis of surgical treatment for 105 cases of ovarian cancer. Guide China Med. 2011;9:140–141.
   Google Scholar
• Ruan G, Ye L, Liu G, An J, Sehouli J, Sun P. The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. Onco Targets Ther. 2018;11:521–528.29416352
   PubMed Web of Science ®Google Scholar
• Lo CS, Sanii S, Kroeger DR, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–934.27601594
   PubMed Web of Science ®Google Scholar
• Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2011;79(1):17–23.20674385
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581–6591.18800822
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(17):523–533. doi:10.1056/NEJMoa170645028578601
   PubMed Web of Science ®Google Scholar
• Tutt A, Kaufman B, Garber JE, Gelber R, McFadden E, OlympiA: GC. A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Ann Oncol. 2015;28:67.
   Google Scholar
• Yarchoan M, Myzak MC, Johnson BA, et al. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget. 2017;8(27):44073–44081. doi:10.18632/oncotarget.1723728454122
   PubMedGoogle Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708. doi:10.1056/NEJMoa150685926510020
   PubMed Web of Science ®Google Scholar
• Fda.gov. FDA approves Lynparza to treat advanced ovarian cancer. Available from: http://fdaguidance.net/wp-content/uploads/2014/12/Lynparza.pdf. Accessed 7 30, 2018.
   Google Scholar
• Fda.gov. FDA approves olaparib tablets for maintenance treatment in ovarian cancer. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm572143.htm. Accessed 730, 2018.
   Google Scholar
• Europa.eu. Lynparza: EPAR-Medicine overview. Available from: http://101.96.10.64/www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003726/WC500180153.pdf. Accessed 730, 2018.
   Google Scholar
• Wiggans AJ, Gemma KSC, Andrew B, Theresa AL, Poly JM. (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2015;5:CD007929 Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub3/full. Accessed July 30, 2018.
   Google Scholar
• HemOnc.org. ovarian cancer. Available from: https://hemonc.org/wiki/Ovarian_cancer#Olaparib_.28%20Lynparza.%2029. Accessed 730, 2018.
   Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014;15(8):852–861. doi:10.1016/S1470-2045(14)70228-124882434
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomized, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–1589. doi:10.1016/S1470-2045(16)30376-X27617661
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–244. doi:10.1016/S0140-6736(10)60892-620609467
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi study analysis of response rates and safety. Ann Oncol. 2016;27(6):1013–1019. doi:10.1093/annonc/mdw13326961146
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–379. doi:10.1200/JCO.2011.36.921522203755
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016;115(11):1313–1320. doi:10.1038/bjc.2016.34827824811
   PubMed Web of Science ®Google Scholar
• Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.25481791
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.28754483
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214.25218906
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2017;35(15 Suppl):5535.
   Google Scholar
• Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126–1134.30026002
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.19553641
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392.22452356
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–251.20609468
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–1706.17148771
   PubMedGoogle Scholar
• Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14(12):3916–3925.18559613
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105(44):17079–17084.18971340
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.22529265
   PubMed Web of Science ®Google Scholar
• González A. Increasing the chances for platinum-sensitive ovarian cancer patients. Future Oncol. 2013;9(12 Suppl):29–35.24195528
   PubMed Web of Science ®Google Scholar
• Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072–1078.23867999
   PubMed Web of Science ®Google Scholar
• Liang JH, Luo RL. Therapeutic effects and safety of olaparib on treatment of recurrent serosity ovarian cancer: a meta-analysis. J Hubei Med Univ. 2015;34(6):538–547.
   Google Scholar
• Liu J. Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02446600. NLM identifier: NCT02446600 Accessed 730, 2018.
   Google Scholar
• Lee J. Cediranib maleate and olaparib or standard chemotherapy in treating patients with recurrent platinum-resistant or-refractory ovarian, fallopian tube, or primary peritoneal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02502266. NLM identifier: NCT02502266. Accessed 730, 2018.
   Google Scholar
• Gourley C, Aghajanian C. Olaparib maintenance treatment versus placebo in patients with PSR ovarian cancer who are in CR or PR to platinum-based chemotherapy and whose tumors carry sBRCAm or HRR-associated genes mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT02392676. NLM identifier: NCT02392676. Accessed 730, 2018.
   Google Scholar
• McGregor N, Vakirtzis T. Olaparib +/- cediranib or chemotherapy in patients with BRCA mutated platinum-resistant ovarian cancer (OCTOVA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03117933. NLM identifier: NCT03117933 Accessed 730, 2018.
   Google Scholar
• DiSilvestro P, Moore K. Olaparib maintenance monotherapy in patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy. (SOLO-1). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01844986. NLM identifier: NCT01844986 Accessed 730, 2018.
   Google Scholar
• Es L. Olaparib treatment in relapsed germline breast cancer susceptibility gene (BRCA) mutated ovarian cancer patients who have progressed at least 6 months after last platinum treatment and have received at least 2 prior platinum treatments (SOLO3). Available from: https://www.clinicaltrials.gov/ct2/show/NCT022820200. NLM identifier: NCT022820200 Accessed 730, 2018.
   Google Scholar
• Morra F, Merolla F, Napolitano V, et al. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. Oncotarget. 2017;8(19):31815–31829.28415632
   PubMedGoogle Scholar